Nanobiotix News

Earnings Call Summary | Nanobiotix(NBTX.US) Q4 2023 Earnings Conference

The following is a summary of the Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript:Financial Performance:Nanobiotix entered into a $2.5 billion license agreement with Johnson Pharmaceutical in

Futu NewsApr 28 00:11 · Conference Call

Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript

Good day and welcome to the Nanobiotix Business Update and Full-Year 2023 Financial Results Conference Call. At this time all participants’ are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded.

Earnings Call TranscriptsApr 27 23:51

Nanobiotix's Revenue at Risk: The High Stakes of Sole Dependence on Janssen Partnership

TipRanksApr 26 14:01

Nanobiotix FY 2023 GAAP EPS $(1.17) Beats $(1.66) Estimate, Sales $39.323M Beat $13.680M Estimate

Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.66) by 29.52 percent. This is a 32.37 percent increase over losses of $(1.73) p

BenzingaApr 25 05:42

Nanobiotix Sa ADR Reports Promising 2023 Progress

TipRanksApr 25 05:27

Nanobiotix 2023 Rev EUR36.2M >NANO.FR

Nanobiotix 2023 Rev EUR36.2M >NANO.FR

Dow JonesApr 25 04:41

Press Release: NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results -- Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV ("Janssen"

Dow JonesApr 25 04:40

Nanobiotix Sa ADR Sets Q4 and Full Year Results Date

TipRanksApr 18 04:57

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

PARIS and CAMBRIDGE, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients

GlobeNewswireApr 18 04:15

CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling over 150 points on Thursday. Shares of CarMax, Inc. (NYSE:KMX) fell sharply in today's pre-market trading after the company r

BenzingaApr 11 20:03

Nanobiotix Sa ADR Updates Share Capital Info

TipRanksApr 11 16:40

Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer

Nanobiotix (NBTX) said late Tuesday it completed the dose escalation part of a phase 1 study evaluating potential first-in-class radioenhancer NBTXR3 for patients with non-small cell lung cancer. The

MT NewswiresApr 3 05:22

Nanobiotix Announces Completion Of Phase 1 Dose Escalation And NBTXR3 Recommended Phase 2 Dose For The Treatment Of Inoperable, Recurrent Lung Cancer In Patients Amenable To Re-Irradiation

Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer ("NSCLC") who have previously received definitive radiation therapyCo

BenzingaApr 3 04:17

Logitech, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining by around 100 points on Monday. Shares of Logitech International S.A. (NASDAQ:LOGI) fell in today's pre-market trad

BenzingaMar 18 17:57

EQT, Genie Energy And Other Big Stocks Moving Lower On Monday

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

BenzingaMar 11 22:37

Nanobiotix to Present at Upcoming Investor Conferences in March

PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients

GlobeNewswireMar 7 05:15

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients

GlobeNewswireFeb 1 05:15

Baillie Gifford Bolsters Stake in Nanobiotix SA

Yahoo FinanceJan 31 00:02

General Motors Posts Upbeat Earnings, Joins Corning, HCA Healthcare And Other Big Stocks Moving Higher On Tuesday

U.S. stocks traded slightly lower, with the Dow Jones falling around 20 points on Tuesday. Shares of General Motors Company (NYSE:GM) rose sharply during Tuesday's session after the company reported

BenzingaJan 30 23:09

UBS Keeps Their Buy Rating on Nanobiotix (NBTX)

TipRanksJan 30 17:25